Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash Flows From Operating Activities
Net loss	$ (47,896)	$ (42,603)	$ (22,548)
Adjustments to reconcile net loss to net cash and cash equivalents (used in)/provided by operating activities:
Stock-based compensation	14,599	10,489	12,936
Deferred taxes	(15,253)	(16,754)	(13,205)
Depreciation and amortization	59,653	47,252	44,638
Acquired in-process research and development ("IPR&D")	1,151		3,753
Non-cash interest	3,961	2,512	1,876
Contingent consideration fair value adjustment	4,058	500
Loss on extinguishment of debt		1,458
Asset impairment charges	574	2,374	445
Gain on sale of ANDAs	(750)	(1,822)
Changes in operating assets and liabilities, net of acquisition:
Accounts receivable, net	(36,912)	(5,548)	(23,664)
Inventories, net	(23,626)	3,224	(2,759)
Prepaid expenses and other current assets	(798)	127	(1,866)
Accounts payable	5,038	10,166	(2,294)
Accrued royalties	3,082	(267)	1,323
Current income taxes payable, net	(160)	(7,573)	4,982
Accrued government rebates	5,380	(3,078)	(1,075)
Returned goods reserve	(2,399)	6,503	10,369
Accrued expenses, accrued compensation, and other	(905)	(3,638)	2,356
Net Cash and Cash Equivalents (Used in)/Provided by Operating Activities	(31,203)	3,322	15,267
Cash Flows From Investing Activities
Acquisition of Novitium Pharma LLC, net of cash acquired	(33)	(84,494)
Acquisition of product rights, IPR&D, and other related assets	(7,579)	(21,081)	(62,187)
Acquisition of property and equipment, net	(8,876)	(2,557)	(6,135)
Proceeds from the sale of long-lived assets	750	2,649
Net Cash and Cash Equivalents Used in Investing Activities	(15,738)	(105,483)	(68,322)
Cash Flows From Financing Activities
Payments on Term Loan and Delayed Draw Term Loan agreements		(10,862)
Payments on borrowings under credit agreements	(3,000)		(8,034)
Payments on Revolver agreement			(7,500)
Borrowings under Prior Revolver agreement		24,000	15,000
Repayment of Prior Credit Facility		(200,148)
Borrowings under the Credit Facility		300,000
Proceeds from issuance of convertible preferred stock		25,000
Series A convertible preferred stock dividends paid	(1,625)	(190)
Proceeds from issuance of common stock in public offering		75,000
Cash paid for costs of share issuances		(5,416)
Proceeds from stock option exercises and ESPP purchases	1,458	2,069	618
Payments of debt issuance costs		(13,968)
Treasury stock purchases for restricted stock vests	(1,959)	(890)	(1,523)
Net Cash and Cash Equivalents (Used in)/Provided by Financing Activities	(5,126)	194,595	(1,439)
Net Change in Cash and Cash Equivalents	(52,067)	92,434	(54,494)
Cash, cash equivalents, and restricted cash, beginning of period	105,301	12,867	67,361
Cash, cash equivalents, and restricted cash, end of period	53,234	105,301	12,867
Reconciliation of cash, cash equivalents, and restricted cash
Cash and cash equivalents	48,228	100,300	7,864
Restricted cash	5,006	5,001	5,003
Total cash, cash equivalents, and restricted cash	53,234	105,301	12,867
Supplemental disclosure for cash flow information:
Cash paid for interest, net of amounts capitalized	21,477	9,705	6,931
Cash paid for income taxes	288	10,371	4,984
Supplemental non-cash investing and financing activities:
Fair value of contingent consideration in a business combination		30,500
Fair value of equity issued as consideration in a business combination		91,199
Acquisition of product rights included in accounts payable	1,000		391
Property and equipment purchased and included in accounts payable	$ 452	$ 152	$ 172